Entrada Therapeutics
TRDA
62 hedge funds and large institutions have $397M invested in Entrada Therapeutics in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
13% more funds holding
Funds holding: 55 → 62 (+7)
0.5% more ownership
Funds ownership: 78.26% → 78.76% (+0.5%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less capital invested
Capital invested by funds: $411M → $397M (-$14.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AACP
Advantage Alpha Capital Partners
San Francisco,
California
|
+$1.56M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$1.48M |
| 3 |
BlackRock
New York
|
+$1.45M |
| 4 |
Bank of New York Mellon
New York
|
+$713K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$664K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
7IH
72 Investment Holdings
Stamford,
Connecticut
|
-$4.98M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$690K |
| 3 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
-$221K |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$158K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$64.8K |
TRDA Hedge Fund Activity: Q4 2023 in Review
62 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q4 2023, worth a combined $397M — down 3.6% from $411M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TRDA positions and 3 closed out — a net gain of 7 holders — while 22 added to existing stakes and 14 trimmed.
The largest buyer was Advantage Alpha Capital Partners, opening a new position worth an estimated $1.56M. The largest seller was 72 Investment Holdings, cutting an estimated $4.98M.
- 62 institutional investors held Entrada Therapeutics (TRDA) as of Q4 2023, up from 55 in Q3 2023.
- Funds reported $397M of Entrada Therapeutics stock for Q4 2023, down 3.6% quarter-over-quarter.
- 10 funds opened new Entrada Therapeutics positions in Q4 2023 and 3 closed out, a net change of +7 holders.
- The largest Entrada Therapeutics buyer in Q4 2023 was Advantage Alpha Capital Partners, an estimated $1.56M added.
- The largest Entrada Therapeutics seller in Q4 2023 was 72 Investment Holdings, an estimated $4.98M sold.
Based on aggregated 13F filings for Q4 2023.